Regulations and Transparency

United States (Strict Disclosure)

The FDA requires direct-to-consumer (DTC) pharmaceutical ads to mention major risks and direct viewers to additional information.

TV and print ads list common side effects, but they often do so quickly or in fine print.

European Union (Limited DTC Ads)

The EU heavily restricts DTC medicine ads, allowing them only for non-prescription drugs.

Side effects are usually disclosed in patient leaflets rather than in ads.

Other Countries (Varied Approaches)

Countries like Canada and Australia allow limited DTC ads but enforce side-effect disclosure rules.

Many nations prohibit DTC prescription drug ads altogether.

Issues with Transparency

Downplaying Risks: Some ads minimize side effects by presenting them quickly or alongside positive visuals.

Omission of Rare Side Effects: Not all potential risks are mentioned in short ads.

Medical Jargon: Ads may use complex terminology that the average consumer might not fully understand.

Digital Advertising Challenges

Online platforms may provide targeted medicine ads with less emphasis on side effects.

Social media influencers promoting medications may not always disclose risks properly.